Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• Heat-shock protein 90 (Hsp90) is a crucial molecular chaperone for cancer cell growth and survival.
• Many Hsp90 client proteins are overexpressed or mutated in cancer, making them therapeutic targets.
• Hsp90 inhibition can lead to the simultaneous degradation of multiple oncoproteins.

Purpose of the Study:

• To review current and emerging strategies for inhibiting Hsp90 function.
• To highlight the mechanisms of action for various Hsp90 inhibitors.
• To discuss the potential of novel Hsp90 modulators in cancer therapy.

Main Methods:

• Review of existing literature on Hsp90 inhibitors.
• Synopsis of compounds targeting Hsp90 directly, allosterically, or indirectly.
• Analysis of proposed mechanisms of action for different inhibitor classes.

Main Results:

• Most current Hsp90 inhibitors target the N-terminal ATP-binding domain, leading to oncoprotein degradation.
• Clinical trials reveal challenges including heat-shock response, retinopathy, and gastrointestinal toxicity.
• Novobiocin derivatives and other natural/synthetic compounds offer alternative inhibition strategies with different mechanisms.

Conclusions:

• Hsp90 inhibition is a viable anticancer strategy, but current inhibitors face clinical limitations.
• Novel Hsp90 inhibitors with diverse mechanisms are under investigation.
• These compounds represent new chemotypes and valuable tools for studying Hsp90 biology.